<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02769013</url>
  </required_header>
  <id_info>
    <org_study_id>Transmal study version 2.0</org_study_id>
    <nct_id>NCT02769013</nct_id>
  </id_info>
  <brief_title>Assessing the Effect of Neglected Tropical Diseases on Plasmodium Falciparum Transmission in an Area of Co-endemicity</brief_title>
  <acronym>TRANSMAL</acronym>
  <official_title>Assessing the Effect of Neglected Tropical Diseases on Plasmodium Falciparum Transmission in an Area of Co-endemicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing the effect of neglected tropical diseases on Plasmodium falciparum transmission in&#xD;
      an area of co endemicity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The project is divided in three different work packages that cover the life cycle of P.&#xD;
      falciparum :&#xD;
&#xD;
        1. In Work Package 1 (WP1) the investigators will assess whether S. haematobium infection&#xD;
           increases the human reservoir of P. falciparum by increasing the carriage rate and&#xD;
           incidence of P. falciparum gametocytaemia as well as by increasing the proportion and&#xD;
           incidence of subject with sub-microscopic P. falciparum infection. The investigators&#xD;
           will also determine whether this increase in gametocyte carriage is a consequence of an&#xD;
           impairment of the immune response of helminth infected subjects to P. falciparum.&#xD;
&#xD;
        2. In Work Package 2 (WP2) the investigators will determine whether the transmission of the&#xD;
           sexual forms of P. falciparum from the human host to mosquito is increased in S.&#xD;
           haematobium infected subjects compared to uninfected controls. Moreover the&#xD;
           investigators will study whether the immunological changes induced in S. haematobium&#xD;
           infected subjects lead to a decrease of the transmission reducing activity of IgG&#xD;
           specific to Pfs48/45 and Pfs230 (both capable of blocking/impairing further development&#xD;
           of P. falciparum in the mosquito gut).&#xD;
&#xD;
        3. Finally in Work Package 3 (WP3) the investigators will assess whether S. haematobium&#xD;
           infection affects the transmission of P. falciparum from the mosquito to the human host.&#xD;
           This effect will be determined indirectly by assessing whether S. haematobium infected&#xD;
           subjects are more attractive to mosquitoes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">October 2020</completion_date>
  <primary_completion_date type="Actual">October 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Plasmodium falciparum gametocytes and/or asexual blood stages</measure>
    <time_frame>15 months</time_frame>
    <description>Presence of Plasmodium falciparum gametocytes and/or asexual blood stages will be assessed by a quantitative real-time PCR assay in the blood obtained from participants. Unit of measurements for both parameters is numbers/µl.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with positive serum antibodies specific to the asexual and gametocyte stages of Plasmodium falciparum.</measure>
    <time_frame>15 months</time_frame>
    <description>Number of participants with serum antibodies against P. falciparum gametocyte and/or asexual blood stage antigens will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of mosquitoes attracted to Schistosoma-infected participants to non-infected individuals in a wind-tunnel assay.</measure>
    <time_frame>15 months</time_frame>
    <description>100 mosquitoes will be released to Schistosoma infected and non-infected participants simultaneously lying in different tents in a two-way olfactometer.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of Plasmodium infected Anopheles mosquitoes per individual per night</measure>
    <time_frame>3 months</time_frame>
    <description>Mosquitoes will be collected by Human Landing catches and species of mosquitoes and presence of Plasmodium falciparum will be determined by morphology and PCR.</description>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">380</enrollment>
  <condition>Malaria Transmission</condition>
  <arm_group>
    <arm_group_label>S. haematobium positives in Gabon</arm_group_label>
    <description>Asymptomatic volunteers infected with S. haematobium and living in Gabon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S. haematobium negatives in Gabon</arm_group_label>
    <description>Volunteers not infected with S. haematobium and living in Gabon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S. haematobium positives in Ghana</arm_group_label>
    <description>Asymptomatic volunteers infected with S. haematobium and living in Ghana</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S. haematobium negatives in Ghana</arm_group_label>
    <description>Volunteers not infected with S. haematobium and living in Ghana</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pre-treatment follow up</intervention_name>
    <description>No active intervention; medical support provided if needed</description>
    <arm_group_label>S. haematobium negatives in Gabon</arm_group_label>
    <arm_group_label>S. haematobium negatives in Ghana</arm_group_label>
    <arm_group_label>S. haematobium positives in Gabon</arm_group_label>
    <arm_group_label>S. haematobium positives in Ghana</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>S. haematobium treatment</intervention_name>
    <description>Praziquantel-treatment for S. haematobium positive volunteers</description>
    <arm_group_label>S. haematobium positives in Gabon</arm_group_label>
    <arm_group_label>S. haematobium positives in Ghana</arm_group_label>
    <other_name>Praziquantel-treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Post treatment follow up</intervention_name>
    <description>No active intervention; medical support provided if needed.</description>
    <arm_group_label>S. haematobium negatives in Gabon</arm_group_label>
    <arm_group_label>S. haematobium negatives in Ghana</arm_group_label>
    <arm_group_label>S. haematobium positives in Gabon</arm_group_label>
    <arm_group_label>S. haematobium positives in Ghana</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Olfactometer experiment</intervention_name>
    <description>No active intervention; medical support provided if needed.</description>
    <arm_group_label>S. haematobium negatives in Gabon</arm_group_label>
    <arm_group_label>S. haematobium negatives in Ghana</arm_group_label>
    <arm_group_label>S. haematobium positives in Gabon</arm_group_label>
    <arm_group_label>S. haematobium positives in Ghana</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample and urine collection potentially containing genetic material of Plasmodium&#xD;
      falciparum and Schistosoma haematobium&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population are subjects aged from 6 to 30 years since both adults and children&#xD;
        have been shown to be a reservoir of P. falciparum. Participants will be recruited in two&#xD;
        African villages located in Gabon (lambarene) and Ghana Asokwa submetropolitan area in&#xD;
        Kumasi, Ghana. Settings in the two locations are different and represent a rural area with&#xD;
        very high infectious pressure from helminths infection (S. haematobium and geohelminths) as&#xD;
        well as year-round transmission of malaria in the Central African rain forest (Lambaréné)&#xD;
        and a more densely populated area in West Africa with pronounced seasonal variation in&#xD;
        malaria transmission and high endemicity of S. haematobium but very little other&#xD;
        helminthiases due to well-implemented mass treatment campaigns.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects aged from 6 to 30 years&#xD;
&#xD;
          -  Without severe or moderate disease&#xD;
&#xD;
          -  Agreement to be enrolled in the study (written informed consent or consent by the&#xD;
             legal representative and assent)&#xD;
&#xD;
          -  Living in the study area for at least 1 year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anaemia with haemoglobin less than 8g/dl&#xD;
&#xD;
          -  Know sickle cell disease&#xD;
&#xD;
          -  Macroscopic haematuria&#xD;
&#xD;
          -  Any other know severe disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulysse ATEBA NGOA, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CERMEL, Lambarene, GABON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oumou MAIGA, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KCCR, Kumasi, Ghana</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ayôla Akim ADEGNIKA</name>
      <address>
        <city>Lambarene</city>
        <state>Albert Schweitzer Hospital</state>
        <zip>118</zip>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KCCR</name>
      <address>
        <city>Kumasi</city>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Gabon</country>
    <country>Ghana</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>April 21, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2016</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schistosoma haematobium plasmodium falciparum transmission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Praziquantel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

